Trial Profile
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms ERASURE
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 12 Jun 2023 Results assessing the pooled safety of secukinumab up to 52 weeks from two studies (NCT03668613 and NCT02471144) in subgroups of pediatric patients stratified by age and bodyweight, and to present, alongside the pediatric data, the pooled safety data from four pivotal adult secukinumab trials (NCT01365455, NCT01636687, NCT01358578, NCT01555125), published in the American Journal of Clinical Dermatology.
- 10 Feb 2023 Results assessing efficacy and safety of secukinumab through to year 5 of treatment in moderate-to-severe plaque psoriasis in ERASURE and FIXTURE trials, published in the British Journal of Dermatology.
- 01 Nov 2021 Results of pooled analysis of 4 studies (ERASURE [NCT01365455], FIXTURE [NCT01358578], FEATURE [NCT01555125], and JUNCTURE [NCT01636687]) assessing effect of a highly effective psoriasis treatment (secukinumab) on domains of the 3-level EuroQol 5 Dimensions questionnaire (EQ-5D-3L) in patients with moderate-to-severe psoriasis who reported problems at baseline, published in the Journal of Dermatological Treatment.